期刊文献+

^(89)Sr治疗前列腺癌骨转移的研究进展 被引量:18

Strontium-89 for bone metastases from prostate cancer:An update
下载PDF
导出
摘要 89Sr发射最大能量为1.46MeV的纯β射线,物理半衰期50.5d,很快在体内被成骨组织摄取,完全滞留在成骨性骨转移病灶内。在转移灶内的生物半衰期大于50d,而在正常骨内只有14d。在前列腺癌患者的肿瘤骨吸收剂量是正常骨的2~25倍。在骨肿瘤中的吸收剂量是(21±4)至(231±56)cGy/MBq。89Sr是前列腺癌骨转移患者骨痛的有效缓解药物,对骨疼痛的止痛有效率为80%。 Strontium-89(Sr-89)is a pure emitter with maximum beta energy of 1.46 MeV,average beta energy of 0.58 MeV,and a physical half-life of 50.5 days.It is rapidly taken up by bone and preferentially retained at the sites of osseous metastases.Its biological half-life is 50 days at the metastatic sites,but about 14 days only in the normal bone.The dose of its Absorption in the tumor-bearing bone ranges from 21 ± 4 to 231 ± 56 cGy/MBq,2-25 times higher than in the normal bone.Strontium-89 therapy is an effective palliative treatment of bone metastases from prostate cancer,with analgesic effectiveness in 80%.
出处 《中华男科学杂志》 CAS CSCD 北大核心 2010年第3期269-272,共4页 National Journal of Andrology
关键词 89Sr 放射性核素治疗 前列腺癌 骨转移病灶 骨疼痛缓解 strontium-89 radiotherapy prostate carcinoma bone metastasis bone pain palliation
  • 引文网络
  • 相关文献

参考文献24

  • 1Blake GM, Zivanovic MA, McEwan A J, et al. Sr-S9 therapy : Strontiurn kinetics in disseminated carcinoma of the prostate. Eur J Nucl Med, 1986, 12(9) : 447-454.
  • 2Petrovich Z, Baert L, Bagshaw MA, et al. Adenocarcinoma of the prostate: Innovations in management. Am J Clin Oncol, 1997, 20(2) : 111-119.
  • 3Breen SL, Powe JE, Porter AT, et al. Doze estimation in strontium-89 radiotherapy of metastatic prostatic carcinoma. J Nucl Med, 1992, 33(7) : 1316-1323.
  • 4Ben-Josef E, Maughan RL, Vasari S, et al. A direct measurement of strontium-89 activity in bone metastases. Nucl Med Commun, 1995, 16(6) : 452-456.
  • 5Robinson RG, Spicer JA, Preston DF, et al. Treatment of metastatic bone pain with strontium-89. Int J Rad Appl Instrum B, 1987, 14(3): 219-222.
  • 6Harrison J, Day P. Radiation doses and risks from internal emitters. J Radiol Prot, 2008, 28(2) : 137-159.
  • 7Strigari L, Sciuto R, D'Andrea M, et al. Radiopharmaceutical therapy of bone metastases with ^89SRC12, ^186Re-HEDP and ^153Sm-EDTMP: A dosimetric study using Monte Carlo simulation. Eur J Nucl Med Mol Imaging, 2007, 34(7) : 1031-1038.
  • 8Li WB, Hollriegl V, Roth P, et al. Influence of human biokinetics of strontium on internal ingestion dose of ^90Sr and absorbed dose of ^89Sr to organs and metastases. Radiat Environ Biophys, 2008, 47(2) : 225-239.
  • 9McEwan AJ. Use of mdionuclides for the palliation of bone metastases. Semin Radiat Oncol, 2000, 10(2) : 103-114.
  • 10Baczyk M, Czepczynski R, Milecki P, et al. ^89Sr versus ^153Sm- EDTMP : Comparison of treatment efficacy of painful bone metastases in prostate and breast carcinoma. Nucl Med Commun, 2007, 28(4) : 245-250.

二级参考文献26

共引文献32

同被引文献145

引证文献18

二级引证文献77

相关主题

;
使用帮助 返回顶部